Retinoids Act as Multistep Modulators of the Major Histocompatibility Class I Presentation Pathway and Sensitize Neuroblastomas to Cytotoxic Lymphocytes

Cancer Research

Volumn 63, Issue 22, 2003, Pages 8006-8013

  Vertuani, Simona ^a   De Geer, Anna ^a   Levitsky, Victor ^b   Kogner, Per ^a   Kiessling, Rolf ^a   Levitskaya, Jelena ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RETINOIC ACID; RETINOID; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL KILLING; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DISEASE PREDISPOSITION; DRUG EFFECT; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

ANTIGEN PRESENTATION; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; NEUROBLASTOMA; T-LYMPHOCYTES, CYTOTOXIC; TRETINOIN; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0345275861     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Sterba, J. Contemporary therapeutic options for children with high risk neuroblastoma. Neoplasma, 49: 133-140, 2002.
2. Cheung, N. K. Monoclonal antibody-based therapy for neuroblastoma. Curr. Oncol. Rep., 2: 547-553, 2000.
3. Savoldo, B., Heslop, H. E., and Rooney, C. M. The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients. Leuk. Lymphoma, 39: 455-464, 2000.
4. Toes, R. E., Offringa, R., Feltkamp, M. C., Visseren, M. J., Schoenberger, S. P., Melief, C. J., and Kast, W. M. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes. Behring. Inst. Mitt., 72-86, 1994.
5. Williams, A., Peh, C. A., and Elliott, T. The cell biology of MHC class I antigen presentation. Tissue Antigens, 59: 3-17, 2002.
6. York, I. A., Goldberg, A. L., Mo, X. Y., and Rock, K. L. Proteolysis and class I major histocompatibility complex antigen presentation. Immunol. Rev., 172: 49-66, 1999.
7. Groettrup, M., Soza, A., Kuckelkorn, U., and Kloetzel, P. M. Peptide antigen production by the proteasome: complexity provides efficiency, Immunol. Today, 17: 429-435, 1996.
8. Aki, M., Shimbara, N., Takashina, M., Akiyama, K., Kagawa, S., Tamura, T., Tanahashi, N., Yoshimura, T., Tanaka, K., and Ichihara, A. Interferon-γ induces different subunit organizations and functional diversity of proteasomes. J. Biochem. (Tokyo), 115: 257-269, 1994.
9. Fruh, K., and Yang, Y. Antigen presentation by MHC class I and its regulation by interferon g. Curr. Opin. Immunol., 11: 76-81, 1999.
10. Hallermalm, K., Seki, K., Wei, C., Castelli, C., Rivoltini, L., Kiessling, R., and Levitskaya, J. Tumor necrosis factor-α induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood, 98: 1108-1115, 2001,
11. Bouillon, M., Tessier, P., Boulianne, R., Destrempe, R., and Audette, M. Regulation by retinoic acid of ICAM-1 expression on human tumor cell lines. Biochim. Biophys. Acta, 1097: 95-102, 1991.
12. Bouillon, M., and Audette, M. Retinoic acid-stimulated intercellular adhesion molecule-1 expression on SK-N-SH cells: calcium-calmodulin-dependent pathway. Cancer Res., 54: 4144-4149, 1994.
13. Darley, R., Morris, A., Passas, J., and Bateman, W. Interactions between interferon γ and retinoic acid with transforming growth factor β in the induction of immune recognition molecules. Cancer Immunol. Immunother., 37: 112-118, 1993.
14. Reynolds, C. P. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr. Oncol. Rep., 2: 511-518, 2000.
15. Santin, A. D., Hermonat, P. L., Ravagaggi, A., Chiriva-Internati, M., Pecorelli, S., and Parham, G. P. Retinoic acid up-regulates the expression of major histocompatibility complex molecules and adhesion/costimulation molecules (specifically, intercellular adhesion molecule ICAM-1) in human cervical cancer. Am. J. Obstet. Gynecol., 179: 1020-1025, 1998.
16. Reynolds, C. P., and Lemons, R. S. Retinoid therapy of childhood cancer. Hematol. Oncol. Clin. North Am., 15: 867-910, 2001.
17. Levitsky, V., de Campos-Lima, P. O., Frisan, T., and Masucci, M. G. The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J. Immunol., 161: 594-601, 1998.
18. Torsteinsdottir, S., Masucci, M. G., Ehlin-Henriksson, B., Brautbar, C., Bassat, B., Klein, G., and Klein, E. Differentiation dependent sensitivity of human B-cell derived lines to major histocompatibility complex restricted T-cell cytotoxicity. Proc. Natl. Acad. Sci. USA. 83: 5620, 1986.
19. Renkvist, N., Castelli, C., Robbins, P. F., and Parmiani, G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother., 50: 3-15, 2001.
20. Benjamin, R. J., Madrigal, J. I., and Parham, P. Peptide binding to empty HLA B27 molecules of viable human cells. Nature (Lond.), 351: 74-77, 1991.
21. Neefjes, J. J., Smith, L., Gehrmann, M., and Ploegh, H. L. The fate of three subunits of major histocompatibility complex class I molecules. Eur. J. Immunol., 22: 1609-1614, 1992.
22. Ortiz-Navarrete, V., and Hammerling, G. J. Surface appearance and instability of empty H-2 class I molecules under physiological conditions. Proc. Natl. Acad. Sci. USA, 88: 3594-3597, 1991.
23. Cromme, F. V., Airey, J., Heemels, M. T., Ploegh, H. L., Keating, P. J., Stern, P. L., Meijer, C. J., and Walboomers, J. M. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med., 179: 335-340, 1994.
24. Mo, X. Y., Cascio, P., Lemerise, K., Goldberg, A. L., and Rock, K. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides. J. Immunol., 163: 5851-5859, 1999.
25. van Hall, T., Sijts, A., Camps, M., Offringa, R., Melief, C., Kloetzel, P. M., and Ossendorp, F. Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J. Exp. Med., 192: 483-494, 2000.
26. Trapani, J. A., and Smyth, M. J. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol., 2: 735-747, 2002.
27. Zhou, T., Mountz, J. D., and Kimberly, R. P. Immunobiology of tumor necrosis factor receptor superfamily. Immunol. Res., 26: 323-336, 2002.
28. Dredge, K., Marriott, J. B., Todryk, S. M., and Daigleish, A. G. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol. Immunother., 51: 521-531, 2002.
29. Cappello, P., Novelli, F., Forni, G., and Giovarelli, M. Death receptor ligands in tumors. J. Immunother., 25: 1-15, 2002.
30. Santin, A. D., Hermonat, P., Ravaggi, A., Chiriva-Internati, M., Hiserodt, J. C., Tian, E., Carter, C. A., Pecorelli, S., and Parham, G. P. Effects of retinoic acid combined with interferon-γ on the expression of major-histocompatibility-complex molecules and intercellular adhesion molecule-1 in human cervical cancer. Int. J. Cancer, 75: 254-258, 1998.
31. Geary, S. M., and Ashman, L. K. HL-60 myeloid leukaemia cells acquire immuno-stimulatory capability upon treatment with retinoic acid: analysis of the responding population and mechanism of cytotoxic lymphocyte activation. Immunol., 88: 428-440, 1996.
32. Chao, T. Y., Jiang, S. Y., Shyu, R. Y., Yeh, M. Y., and Chu, T. M. All-trans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity. Br. J. Cancer, 75: 1284-1290, 1997.
33. Draper, J. S., Pigott, C., Thomson, J. A., and Andrews, P. W. Surface antigens of human embryonic stem cells: changes upon differentiation in culture. J. Anat., 200: 249-258, 2002.
34. Marozzi, A., Meneveri, R., Bunone, G., De Santis, C., Lopalco, L., Beretta, A., Agresti, a., Siccardi, A., Della Valle, G., and Ginelli, E. Expression of β 2m-free HLA clas I heavy chains in neuroblastoma cell lines. Scand. J. Immunol., 3777: 661-667, 1993.
35. Clark, R. A., Li, S. L., Pearson, D. W., Leidal, K. G., Clark, J. R., Denning, G. M., Reddick, R., Krause, K. H., and Valente, A. J. Regulation of calreticulin expression during induction of differentiation in human myeloid cells. Evidence for remodeling of the endoplasmic reticulum. J. Biol. Chem., 277: 32369-32378, 2002.
36. Lewis, J. W., and Elliott, T. Evidence for successive peptide binding and quality control stages during MHC class I assembly. Curr. Biol., 8: 717-720, 1998.
37. McQueen, K. L., and Parham, P. Variable receptors controlling activation and inhibition of NK cells. Curr. Opin. Immunol., 14: 615-621, 2002.
38. Cerwenka, A., and Lanier, L. L. Ligands for natural killer cell receptors: redundancy or specificity. Immunol. Rev., 181: 158-169, 2001.
39. Alexander, C. L., Edward, M., and MacKie, R. M. The role of human melanoma cell ICAM-1 expression on lymphokine activated killer cell-mediated lysis, and the effect of retinoic acid. Br. J. Cancer. 80: 1494-1500, 1999.
40. Facchetti, P., Prigione, I., Ghiotto, F., Tasso, P., Garaventa, A., and Pistoia, V. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma. Cancer Immunol. Immunother., 42: 170-178, 1996.
41. Yonehara, S., Ishii, A., and Yonehara, M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med., 169: 1747-1756, 1989.